Joshua Pinto

Insider Reports History

Location
Watertown, MA
Signature
/s/ Matthew Lang, Attorney-in-Fact for Joshua Pinto
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Joshua Pinto:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Neumora Therapeutics, Inc. President Common Stock 152K $117K $0.77 May 21, 2025 Indirect
Neumora Therapeutics, Inc. President Common Stock 63.8K $49.1K $0.77 May 21, 2025 Direct
Metsera, Inc. Director Common Stock 0 $0 $52.33 Nov 13, 2025 Direct
Neumora Therapeutics, Inc. President Stock Option (Right to Buy) 3M May 28, 2025 Direct
Metsera, Inc. Director Restricted Stock Unit 2.69K Nov 13, 2025 Direct
Metsera, Inc. Director Stock Option (right to buy) 0 Nov 13, 2025 By LLC
Metsera, Inc. Director Stock Option (right to buy) 0 Nov 13, 2025 Direct

Insider Reports Filed by Joshua Pinto

Symbol Company Period Transactions Value $ Form Type Date Filed Role
MTSR Metsera, Inc. Nov 13, 2025 4 $0 4 Nov 13, 2025 Director
NMRA Neumora Therapeutics, Inc. May 28, 2025 14 $0 4 May 30, 2025 President
NMRA Neumora Therapeutics, Inc. May 21, 2025 2 $0 4 May 23, 2025 President
MTSR Metsera, Inc. May 20, 2025 3 $0 4 May 22, 2025 Director
NMRA Neumora Therapeutics, Inc. Feb 18, 2025 1 -$13.5K 4 Feb 20, 2025 President
NMRA Neumora Therapeutics, Inc. Feb 13, 2025 13 $0 4 Feb 18, 2025 President
MTSR Metsera, Inc. Jan 30, 2025 0 $0 3 Jan 30, 2025 Director
NMRA Neumora Therapeutics, Inc. Aug 27, 2024 1 -$179K 4 Aug 27, 2024 Chief Financial Officer
NMRA Neumora Therapeutics, Inc. Aug 22, 2024 3 -$984K 4 Aug 26, 2024 Chief Financial Officer
NMRA Neumora Therapeutics, Inc. Apr 17, 2024 1 $0 4 Jun 28, 2024 Chief Financial Officer
NMRA Neumora Therapeutics, Inc. Feb 14, 2024 2 $0 4 Feb 16, 2024 Chief Financial Officer
NMRA Neumora Therapeutics, Inc. Sep 14, 2023 0 $0 3 Sep 14, 2023 Chief Financial Officer